KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Johnson & Johnson (JNJ) Non-cash Items (2010 - 2012)

Johnson & Johnson recorded quarterly Non-cash Items of $1.0 billion in Q1 2012, up 710570.68% quarter-over-quarter from $141275.0 in Q1 2011, and up 710570.68% year-over-year from N/an in Q1 2011.

Johnson & Johnson's Non-cash Items history runs 3 years deep, the most recent figure standing at $1.0 billion for Q1 2012.

  • In Q1 2012, Non-cash Items rose 710570.68% year-over-year to $1.0 billion; the TTM figure through Jan 2012 stood at $1.0 billion (up 710570.68% YoY), while the FY2012 annual figure was $1.0 billion, up 710570.68% from the prior year.
  • Non-cash Items came in at $1.0 billion for Q1 2012 at Johnson & Johnson, up from $141275.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $1.3 billion in Q1 2010 to a low of $141275.0 in Q1 2011.
  • A 3-year average of $771.4 million and a median of $1.0 billion in 2012 frame the typical range for Non-cash Items.
  • Across the five-year window, Non-cash Items plunged 99.99% in 2011 and jumped 710570.68% in 2012, its largest moves.
  • Johnson & Johnson's Non-cash Items stood at $1.3 billion in 2010, then slumped by 99.99% to $141275.0 in 2011, then surged by 710570.68% to $1.0 billion in 2012.
  • According to Business Quant data, Non-cash Items over the past three periods registered $1.0 billion, $141275.0, and $1.3 billion for Q1 2012, Q1 2011, and Q1 2010 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Jan 1, 2012 1.00 Bn
Jan 1, 2012 1.00 Bn
Jan 2, 2011 141,275.00
Jan 2, 2011 141,275.00
Jan 3, 2010 1.31 Bn
Jan 3, 2010 1.31 Bn